moxonidine has been researched along with Heart Failure in 20 studies
moxonidine: structure given in first source
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although beta-adrenergic blockade is beneficial in heart failure, inhibition of central sympathetic outflow using moxonidine has been associated with increased mortality." | 9.12 | Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. ( Andersson, B; Bergh, CH; Fu, M; Jansson, PA; Mobini, R; Scharin Täng, M; Waagstein, F, 2006) |
| "The association between sympathetic activation and mortality in chronic heart failure and the favorable effect of beta blocking drugs has raised the possibility of therapeutic efficacy for central sympathetic inhibition with sustained-release (SR) moxonidine, an imidazoline receptor agonist." | 9.10 | Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). ( Cohn, JN; Pfeffer, MA; Rouleau, J; Sharpe, N; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2003) |
| "A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0." | 9.10 | Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002) |
| "To evaluate the dose response relationship of moxonidine on plasma concentration of norepinephrine during acute and chronic administration in patients with congestive heart failure (CHF)." | 9.09 | The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. ( Bergh, CH; Dickstein, K; McNay, J; Steinberg, M; Swedberg, K, 2000) |
| "To assess the pharmacodynamics of moxonidine in patients with functional NYHA Class II-III congestive heart failure (CHF)." | 9.09 | Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. ( Brynne, L; Karlsson, MO; McNay, JL; Schaefer, HG; Swedberg, K; Wiltse, CG, 2001) |
| "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure." | 7.79 | Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013) |
| "Deriving a population pharmacokinetic model from real data is always associated with numerous assumptions." | 6.69 | Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. ( Jonsson, EN; Karlsson, MO; Wade, JR; Wiltse, CG, 1998) |
| "Moxonidine was well tolerated in this single-dose study and resulted in a modest, dose-dependent, vasodilator response, with substantial reductions in systemic and pulmonary arterial blood pressure." | 6.69 | Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Aarsland, T; Dickstein, K; Køpp, U; Manhenke, C; McNay, J; Wiltse, C, 1999) |
| "Although beta-adrenergic blockade is beneficial in heart failure, inhibition of central sympathetic outflow using moxonidine has been associated with increased mortality." | 5.12 | Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. ( Andersson, B; Bergh, CH; Fu, M; Jansson, PA; Mobini, R; Scharin Täng, M; Waagstein, F, 2006) |
| "The MOXonidine CONgestive Heart Failure trial was a randomized comparison of moxonidine, a central sympathetic inhibitor, with placebo." | 5.11 | The data monitoring experience in the MOXCON trial. ( Dickstein, K; Francis, G; Pocock, S; Wilhelmsen, L; Wittes, J, 2004) |
| "The association between sympathetic activation and mortality in chronic heart failure and the favorable effect of beta blocking drugs has raised the possibility of therapeutic efficacy for central sympathetic inhibition with sustained-release (SR) moxonidine, an imidazoline receptor agonist." | 5.10 | Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). ( Cohn, JN; Pfeffer, MA; Rouleau, J; Sharpe, N; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2003) |
| "A total of 268 patients with chronic heart failure in NYHA functional class II to IV on optimal standard therapy were randomized to placebo or 1 of 5 doses of moxonidine SR: 0." | 5.10 | Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Dargie, H; Straub, M; Swedberg, K; Wiltse, C; Wright, TJ, 2002) |
| "To evaluate the dose response relationship of moxonidine on plasma concentration of norepinephrine during acute and chronic administration in patients with congestive heart failure (CHF)." | 5.09 | The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators. ( Bergh, CH; Dickstein, K; McNay, J; Steinberg, M; Swedberg, K, 2000) |
| "To assess the pharmacodynamics of moxonidine in patients with functional NYHA Class II-III congestive heart failure (CHF)." | 5.09 | Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. ( Brynne, L; Karlsson, MO; McNay, JL; Schaefer, HG; Swedberg, K; Wiltse, CG, 2001) |
| "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure." | 3.79 | Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013) |
| "6 hamsters (6 and 10 months old, with moderate and advanced heart failure, respectively) received moxonidine at 2 concentrations: low (2." | 3.77 | Functional and molecular effects of imidazoline receptor activation in heart failure. ( Abdel Rahman, AA; Aceros, H; Mukaddam-Daher, S; Noiseux, N; Stabile, AM; Stockmeyer, K, 2011) |
| "Deriving a population pharmacokinetic model from real data is always associated with numerous assumptions." | 2.69 | Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. ( Jonsson, EN; Karlsson, MO; Wade, JR; Wiltse, CG, 1998) |
| "Moxonidine was well tolerated in this single-dose study and resulted in a modest, dose-dependent, vasodilator response, with substantial reductions in systemic and pulmonary arterial blood pressure." | 2.69 | Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Aarsland, T; Dickstein, K; Køpp, U; Manhenke, C; McNay, J; Wiltse, C, 1999) |
| "Moxonidine has unique effects on a number of cell types through this unusual cellular site of action." | 2.48 | Pharmacological properties of the central antihypertensive agent, moxonidine. ( Brown-Bryan, TA; Edwards, LP; Ernsberger, P; McLean, L, 2012) |
| "Moxonidine also has beneficial effects in animal models of diabetes and kidney disease." | 2.41 | Moxonidine: some controversy. ( Doggrell, SA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, N | 1 |
| Hirooka, Y | 1 |
| Ito, K | 1 |
| Matsukawa, R | 1 |
| Shinohara, K | 1 |
| Kishi, T | 1 |
| Yasukawa, K | 1 |
| Utsumi, H | 1 |
| Sunagawa, K | 1 |
| Stabile, AM | 1 |
| Aceros, H | 1 |
| Stockmeyer, K | 1 |
| Abdel Rahman, AA | 1 |
| Noiseux, N | 1 |
| Mukaddam-Daher, S | 1 |
| Edwards, LP | 1 |
| Brown-Bryan, TA | 1 |
| McLean, L | 1 |
| Ernsberger, P | 1 |
| Lechin, F | 1 |
| Lechin, M | 1 |
| van der Dijs, B | 1 |
| Cohn, JN | 2 |
| Pfeffer, MA | 1 |
| Rouleau, J | 1 |
| Sharpe, N | 1 |
| Swedberg, K | 4 |
| Straub, M | 2 |
| Wiltse, C | 4 |
| Wright, TJ | 2 |
| Pocock, S | 1 |
| Wilhelmsen, L | 1 |
| Dickstein, K | 4 |
| Francis, G | 1 |
| Wittes, J | 1 |
| Mobini, R | 1 |
| Fu, M | 1 |
| Jansson, PA | 1 |
| Bergh, CH | 2 |
| Scharin Täng, M | 1 |
| Waagstein, F | 1 |
| Andersson, B | 1 |
| Karlsson, MO | 2 |
| Jonsson, EN | 1 |
| Wiltse, CG | 2 |
| Wade, JR | 1 |
| Manhenke, C | 2 |
| Aarsland, T | 2 |
| Køpp, U | 1 |
| McNay, J | 3 |
| Coats, AJ | 1 |
| Bousquet, P | 1 |
| Feldman, J | 1 |
| Steinberg, M | 1 |
| Van Kerckhoven, R | 1 |
| van Veen, TA | 1 |
| Boomsma, F | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
| Wright, T | 1 |
| Brynne, L | 1 |
| McNay, JL | 1 |
| Schaefer, HG | 1 |
| Doggrell, SA | 1 |
| van Veldhuisen, DJ | 1 |
| Poole-Wilson, PA | 1 |
| Floras, JS | 1 |
| Bristow, MR | 1 |
| Dargie, H | 1 |
4 reviews available for moxonidine and Heart Failure
| Article | Year |
|---|---|
Pharmacological properties of the central antihypertensive agent, moxonidine.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Central Nervous System; Heart Failure; Humans; Hyp | 2012 |
Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Heart Failure; Hum | 1999 |
Moxonidine: some controversy.
Topics: Adrenergic Agonists; Animals; Antihypertensive Agents; Disease Models, Animal; Heart Failure; Humans | 2001 |
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Py | 2001 |
10 trials available for moxonidine and Heart Failure
| Article | Year |
|---|---|
Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
Topics: Delayed-Action Preparations; Double-Blind Method; Female; Heart Failure; Humans; Imidazoles; Male; M | 2003 |
The data monitoring experience in the MOXCON trial.
Topics: Clinical Trials Data Monitoring Committees; Decision Making; Heart Failure; Humans; Imidazoles; Publ | 2004 |
Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
Topics: Aged; Antihypertensive Agents; Fatty Acids, Nonesterified; Female; Heart; Heart Failure; Hemodynamic | 2006 |
Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.
Topics: Adult; Aged; Double-Blind Method; Female; Heart Failure; Humans; Imidazoles; Male; Middle Aged; Mode | 1998 |
Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Cardiomyopathy, Dilated; | 1999 |
Heart Failure 99 -- the MOXCON story.
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Chronic Disease; Dose-Response Rel | 1999 |
The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. Moxonidine Investigators.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Chromatography, High Pressure Liquid; Dose-Response R | 2000 |
The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
Topics: Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Female; Heart Failure; Heart Rate; | 2000 |
Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.
Topics: Adult; Aged; Algorithms; Anti-Arrhythmia Agents; Blood Pressure; Female; Heart Failure; Heart Rate; | 2001 |
Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
Topics: Blood Pressure; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doub | 2002 |
6 other studies available for moxonidine and Heart Failure
| Article | Year |
|---|---|
Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure.
Topics: Animals; Antihypertensive Agents; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Imidaz | 2013 |
Functional and molecular effects of imidazoline receptor activation in heart failure.
Topics: Animals; Apoptosis; Blotting, Western; Collagen; Cricetinae; Cytokines; Disease Models, Animal; Dose | 2011 |
Plasma catecholamines and chronic congestive heart failure.
Topics: Adrenal Glands; Catecholamines; Chronic Disease; Clonidine; Diagnostic Techniques, Cardiovascular; D | 2002 |
[Moxonidin in heart failure: new therapeutic principles suppress neurohumoral activation. Supplement to the Congress on "Heart Failure" of the working group on cardiac insufficiency at the European Society for Cardiology. Cologne, May 1997].
Topics: Antihypertensive Agents; Cardiology; Europe; Heart Failure; Humans; Imidazoles; Neurotransmitter Age | 1997 |
Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Collagen; Disease Models, Animal; Dose-Respon | 2000 |
The "unsympathetic" nervous system of heart failure.
Topics: Clinical Trials as Topic; Double-Blind Method; Heart Failure; Humans; Imidazoles; Norepinephrine; Sy | 2002 |